13 research outputs found

    A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR.

    No full text
    BackgroundAquaporin 4 (AQP4) is considered a putative autoantigen in patients with Neuromyelitis optica (NMO), an autoinflammatory disorder of the central nervous system (CNS). HLA haplotype analyses of patients with NMO suggest a positive association with HLA-DRB1* 03:01. We previously showed that the human (h) AQP4 peptide 281-300 is the dominant immunogenic determinant of hAQP4 in the context of HLA-DRB1*03:01. This immunogenic peptide stimulates a strong Th1 and Th17 immune response. AQP4281-300-specific encephalitogenic CD4+ T cells should initiate CNS inflammation that results in a clinical phenotype in HLA-DRB1*03:01 transgenic mice.MethodsControlled study with humanized experimental animals. HLA-DRB1*03:01 transgenic mice were immunized with hAQP4281-300, or whole-length hAQP4 protein emulsified in complete Freund's adjuvant. Humoral immune responses to both antigens were assessed longitudinally. In vivo T cell frequencies were assessed by tetramer staining. Mice were followed clinically, and the anterior visual pathway was tested by pupillometry. CNS tissue was examined histologically post-mortem. Flow cytometry was utilized for MHC binding assays and to immunophenotype T cells, and T cell frequencies were determined by ELISpot assay.ResultsImmunization with hAQP4281-300 resulted in an in vivo expansion of antigen-specific CD4+ T cells, and an immunoglobulin isotype switch. HLA-DRB1*03:01 TG mice actively immunized with hAQP4281-300, or with whole-length hAQP4 protein were resistant to developing a neurological disease that resembles NMO. Experimental mice show no histological evidence of CNS inflammation, nor change in pupillary responses. Subsequent analysis reveals that a single amino acid substitution from aspartic acid in hAQP4 to glutamic acid in murine (m)AQP4 at position 290 prevents the recognition of hAQP4281-300 by the murine T cell receptor (TCR).ConclusionInduction of a CNS inflammatory autoimmune disorder by active immunization of HLA-DRB1*03:01 TG mice with human hAQP4281-300 will be complex due to a single amino acid substitution. The pathogenic role of T cells in this disorder remains critical despite these observations

    Human (h)AQP4<sub>281-300</sub>-specific T cells do not cross-react with murine (m) AQP4<sub>281-300.</sub>

    No full text
    <p>(A) There is that a single amino acid substitution from aspartic acid in hAQP4 to glutamic acid in murine (m)AQP4 at position 290. (B) In lymph node cells of <i>HLA-DRB1*03</i>:<i>01</i> mice immunized with hAQP4<sub>281-300</sub> there was a significant proliferation of CD4<sup>+</sup> T cells when hAQP4<sub>281-300</sub> was used as the recall antigen (* = P-value = 0.01). Only a higher recall antigen dose of 25 μg/ml resulted in a significant increase in proliferation, whereas as a dose of 5 μg/ml did not. (C) There was no proliferative response to mAQP4<sub>281-300</sub> at either dose<sub>.</sub> (D) There is a significantly increased frequency of IFNγ and IL-17 producing lymph nodes cells from <i>HLA-DRB1*03</i>:<i>01</i> mice immunized with hAQP4<sub>281-300</sub> by ELISpot assay when hAQP4<sub>281-300</sub>, and hAQP4<sub>281-299</sub> are used as recall antigens. However, we were unable to detect antigen specific IFNγ and IL-17 producing lymph nodes cells when mAQP4<sub>281-300</sub>, or the negative control hAQP4<sub>66-79</sub> were used as recall antigens (** = P-value < 0.01). (E) IFNγ and IL-17 producing lymph nodes cells from <i>HLA-DRB1*03</i>:<i>01</i> mice immunized with mAQP4<sub>281-300</sub> were undetectable with any of the recall antigens.</p

    <i>HLA-DRB1*03</i>:<i>01</i> transgenic mice are disease resistant to active immunization with human aquaporin 4 (hAQP4), and adoptive transfer of hAQP4-specific T cells.

    No full text
    <p>(A) <i>HLA-DRB1*03</i>:<i>01</i> mice were actively immunized with proteolipid protein (PLP)<sub>91-110</sub> (100 μg/100 μl/mouse; positive control [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0152720#pone.0152720.ref025" target="_blank">25</a>]), or varying AQP4 antigens*(whole-length hAQP4 protein, hAQP4<sub>281-300</sub>, murine (m)AQP4<sub>281-300</sub>, hAQP4<sub>281-300</sub> with a Quil-A Incomplete Freund Adjuvant (IFA) booster on day 14 post-immunization, mAQP4<sub>281-300</sub> with a Quil-A IFA booster on day 14 post immunization, and hAQP4<sub>281-300</sub> plus mAQP4<sub>281-300</sub>) emulsified in Complete Freund Adjuvant (CFA). Immunization with a positive control proteolipid protein (PLP)<sub>91-110</sub>, a dominant encephalitogenic determinant in <i>HLA-DRB1*03</i>:<i>01</i> led to typical EAE. (B) Lymph node cells taken from <i>HLA-DRB1*03</i>:<i>01</i> mice immunized with hAQP4<sub>281-300</sub> or mAQP4<sub>281-300</sub> were restimulated for three days and passively transferred into <i>HLA-DRB1*03</i>:<i>01</i> mice. None of these experimental approaches resulted in clinical disease. (C) Paraffin sections were stained with haematoxlin eosin (H&E) and luxol fast blue (LFB). Representative sections of the spinal cords from PLP<sub>91-110</sub> and hAQP4<sub>281-300</sub> immunized mice are shown. On histopathological examination there were no visible signs of cellular infiltration, inflammation, or demyelination within the brain and spinal cord in any experimental paradigms other than in active immunization with PLP<sub>91-110</sub>, the dominant encephalitogenic determinant in <i>HLA-DRB1*03</i>:<i>01</i> that led to typical EAE (spinal cord shown; inflammatory infiltrates and areas of demyelination are indicated by black arrows). (D) Fifteen days post immunization of <i>HLA-DRB1*03</i>:<i>01</i> transgenic mice with PLP<sub>91-110</sub> or hAQP4<sub>281-300</sub>, pupillary reflex was measured via a mouse pupillometry. Mice actively immunized with hAQP4<sub>281-300</sub> and the control antigen PLP<sub>91-110</sub> did not show altered pupillary responses.</p

    Human (h)AQP4<sub>284-299</sub> Alanine Scanning Peptides.

    No full text
    <p>The immunogenic region of hAQP4<sub>281-300</sub>, hAQP4<sub>284-299</sub>, was utilized to generate alanine scanning peptides at which each peptide sequence has a single alanine residue mutation.</p

    Immunization with human (h)AQP4<sub>281-300</sub> leads to an expansion of antigen-specific CD4<sup>+</sup> T cells <i>in vivo</i>, and an Ig isotype switch in <i>HLA-DRB1*03</i>:<i>01</i> transgenic mice.

    No full text
    <p>(A) Following immunization with human (h)AQP4<sub>281-300</sub>, an expansion of antigen-specific CD4<sup>+</sup> T helper cells was detected by tetramer staining of lymph node cells. The fluorescent signal of <i>HLA-DRB1*03</i>:<i>01</i>-loaded tetramers minus the fluorescent signal of empty <i>HLA-DRB1*03</i>:<i>01</i> tetramers is shown. CD4<sup>+</sup> T helper cells provide soluble mediators that drive B cell differentiation immunoglobulin (Ig) class switching. To determine whether hAQP4<sub>281-300</sub>-reactive CD4<sup>+</sup> T cells are capable of causing IgM to IgG isotype switching in <i>HLA-DRB1*03</i>:<i>01</i> transgenic mice, the concentration of Ig against hAQP4<sub>281-300</sub>, mAQP4284-299, or with whole-length hAQP4 protein in serum of immunized mice was quantified longitudinally. Since the NMO-IgG is a human IgG1 isotype, both, the murine IgG2a and IgG2b isotype were examined as they have similar properties with regard to complement binding and the Fcγ receptor. A switch from IgM to IgG2b was detected in mice immunized with hAQP4<sub>281-300</sub> peptide with regard to (B) antibody responses against hAQP4<sub>281-300</sub> and (C) whole-length AQP4 protein. An Ig isotype switch from IgM to IgG2b was also detectable in mice immunized with whole-length AQP4 protein with regard to (D) antibody responses against hAQP4<sub>281-300</sub> and (E) whole-length AQP4 protein.</p

    Identification of critical residues of human (h)AQP4<sub>281-300</sub> for presentation in the context of <i>HLA-DRB1*03</i>:<i>01</i> and recognition by the B.10 T cell receptor (TCR).

    No full text
    <p>(A) First, the ability of hAQP4<sub>281-300</sub>-reactive lymph node cells to recognize the alanine screening peptides was determined by ELISpot. 5.0x10<sup>5</sup> cells/well lymph node cells taken ten days post immunization of <i>HLA-DRB1*03</i>:<i>01</i> transgenic mice with hAQP4<sub>281-300</sub> were restimulated with hAQP4 alanine scanning peptides (2 5 μg/mL) for 48 hours in IFNγ and IL-17 ELISpot plates (* = P-value < 0.05 and ** = P-value < 0.01). (B) Alanine screening peptides that not result in an increased frequency of IFNγ and IL-17 secreting lymph node cells were identified as the key residue peptides, and were subsequently tested in a MHC binding assay. Splenocytes taken from <i>HLA-DRB1*03</i>:<i>01</i> transgenic mice were incubated for 12 hours in the presence of biotinylated hAQP4 alanine scanning peptides. Post incubation, cells were stained utilizing FITC-Avidin, and antigen positive cells were quantified by flow cytometry (* = P-value < 0.05 and ** = P-value < 0.01). (C) There was no Ig isotype class switch in mice immunized with mAQP4<sub>284-299</sub> with regard to antibody responses against whole-length AQP4 protein. (D) Critical <i>HLA-DRB1*03</i>:<i>01</i> anchor residues, and B.10 TCR contact amino acids are specified. E<sub>288</sub> and L<sub>294</sub> are required as <i>HLA-DRB1*03</i>:<i>01</i> anchor residues, while T<sub>289</sub>, D<sub>290</sub>, D<sub>291</sub>, and I<sub>293</sub> are critical B.10 TCR interacting residues.</p
    corecore